After Hours
$
7.89
Change
0.00 0.00%
Volume
Volume 79,762
Jul 1, 2022, 5:51 p.m.
Quotes are delayed by 20 min
Today's close
$ 7.52
$ 7.89
Change
+0.37 +4.92%
Day low
Day high
$7.42
$7.91

52 week low
52 week high
$7.23
$10.50

Market cap
$8.47B
Average volume
10.33M
P/E ratio
N/A
Rev. per Employee
$413,885
EPS
-0.56
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on TEVA
-
Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees
- Steve Gelsi
-
Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years
- Steve Gelsi
-
W. Va. says Teva opioid agreement consistent with previously announced settlements
- Steve Gelsi
-
Teva Pharmaceutical upgraded to neutral from underperform at BofA Securities
- Tomi Kilgore
-
Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion
- Barron's Online
-
Teva CEO Sees a Final Opioid Settlement Coming This Year
- Barron's Online
-
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame.
- Barron's Online
-
Teva now sees full-year revenue of $15.4 bln to $16.0 bln vs. prior guidance of $15.6 bln to $16.2 bln
- Ciara Linnane
-
Teva now sees full-year EPS of $2.40 to $2.60, unchanged vs. prior guidance
- Ciara Linnane
-
Teva lowers full-year revenue guidance
- Ciara Linnane
-
Teva Q1 adj. EPS 55 cents; FactSet consensus 53 cents
- Ciara Linnane
-
Teva Q1 revenue $3.661 bln, down 8%; FactSet consensus $3.598 bln
- Ciara Linnane
-
Teva Q1 loss per share 86 cents vs. EPS 7 cents a year ago
- Ciara Linnane
-
Teva, Others to Pay Millions in Florida Opioid Settlements
- Barron's Online
-
Teva Pharmaceutical upgraded to outperform at Bernstein
- Tomi Kilgore
-
Completed Settlements Signal Opioid Litigation Is Drawing to a Close
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Why Teva’s Generic EpiPen Contribution Could Be Modest in 2018
- MarketRealist.com
-
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
- MarketRealist.com
Other News on TEVA
-
- Seeking Alpha
-
CVS, Walmart Impose Purchase Limits on Plan B Pills
- Sharon Terlep
-
Teva Lonquex gets EMA panel backing for expanded use in children
- Seeking Alpha
-
Teva started at neutral at UBS on pricing and legal concerns
- Seeking Alpha
-
Michael Sela Helped Create Blockbuster Drug for Multiple Sclerosis
- James R. Hagerty
-
Defining Risk: Tips To Weather And Profit From The Coming Storm
- Seeking Alpha
-
Teva wins U.K. approval for Lucentis biosimilar
- Seeking Alpha
- Loading more headlines...
Press Releases on TEVA
-
Teva Announces Appointment of New Global R&D and Chief Medical Officer
- BusinessWire - BZX
-
Teva Pharmaceutical (TEVA) Trading Report
- Stock Traders Daily
-
Teva Pharmaceutical TEVA Proactive Strategies
- Stock Traders Daily
-
Migraine Treatment Drugs Market Size, Share | Global Report [2028]
- AmericaNewsHour
-
Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts
- Stock Traders Daily
-
Teva Pharmaceutical (TEVA) Trading Report
- Stock Traders Daily
-
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls
- Stock Traders Daily
-
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls
- Stock Traders Daily
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com